12:00 AM
Jan 17, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

OTS-prochlorperazine: Began Phase I trials

Anesta Corp. (NSTA), Salt Lake City, Utah
Product: OTS-prochlorperazine
Business: Drug delivery, Neurological
Therapeutic category: Drug delivery, Receptor antagonist
Target: Dopamine-2 receptors
Description: Oral transmucosal dopamine-2 antagonist...

Read the full 113 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >